The use of the 7 + 3 protocol followed by high-dose cytarabine consolidation in CBF-AML has demonstrated remission rates of approximately 90% and 3- and 5-year OS rates of 65–70% and 58–65%, respectively [15–19]. This evidence concerns the gene CEBPZ and acute myeloid leukemia.